Caffeine consumption and Parkinson’s disease: a mini-review of current evidence

In the absence of efficient disease-modifying treatments for Parkinson’s disease (PD), research has focused on identifying potential environmental factors whose modulation may prevent or slow progression this neurodegenerative disorder. Compelling epidemiological evidence suggests that caffeine consumption is inversely associated with risk developing PD. Further experimental findings demonstrated caffeine, by particularly targeting adenosine A2A (A2AR) receptors, protected PD animal models against loss dopaminergic neurons. The antagonistic action receptors not only slowed PD-related neurodegeneration, but also improved motor and nonmotor symptoms in models. Here, we review mechanisms which might play a role reducing We current benefits Finally, point out how these promising could lead to identification new approaches effective treatment